SASB Index Report 2023
Fiscal Year Ended March 31, 2023

This index table summarizes the relevant disclosures aligned to the
Biotechnology & Pharmaceuticals Industry Standards of the
Sustainability Accounting Standards Board (SASB). The index supplements
content provided on our overarching sustainability priorities,
commitments and initiatives outlined in our 2023 Annual Integrated
Report and on Takeda.com. More information on the SASB standards canbe found at SASB.org.
Optimizing our ESG Reporting is an iterative process. While we do not yetreport against every indicator within this reporting framework, we will
work to continuously enhance our data capture processes and reporting of
ESG information to demonstrate our commitment to transparency and our
stakeholders.
The reporting period covers FY22 (April 1, 2022 to March 31, 2023) unlessotherwise specified. Select performance indicators assured by Apex
Companies, LLC ☑ and KPMG AZSA Sustainability Co., Ltd (KPMG) ☑,independent professional services companies and are denoted with therespective symbol.
A copy of the assurance statement can be found in our 2023 Sustainability
Disclosure.

SASB MetricTakeda disclosure

Safety of Clinical Trial Participants
Clinical trials are conducted in accordance with scientifically designed protocols, which balance potential risk to the research participants
with the possible benefit to the participant and to society. We conduct trials in compliance with legal and regulatory requirements, and weare committed to applicable international principles and standards, including the Declaration of Helsinki 2013, the Good Clinical Practice(GCP) Standard of the International Conference on Harmonization (ICH), European Federation of Pharmaceutical Industries andAssociations/Pharmaceutical Research and Manufacturers of America (PhRMA) Principles.
We also apply our values and ethical standards to the design and conduct of clinical trials, informed consent processes and stewardship ofparticipant data. Clinical trials are designed to contribute to the well-being of research participants and patients, and to help build
knowledge. We provide participants with a thorough explanation of expected benefits and potential side effects and follow an informed
consent process that supports participants’ ability to choose to participate in the trial. Processes are designed to help ensure the wellbeing of research participants and to respect patient privacy and confidential information.

HC-BP-210a.1

Discussion, by world
region, of management
process for ensuring
quality and patient safety
during clinical trials

Our principal investigators and sub investigators at clinical trial sites agree to operate in line with the ICH GCP and other applicableprinciples and standards. We train our employees involved in clinical trials in Takeda’s policies and the Standard Operating Procedures
relevant to their position, including our Code of Conduct, Ethics & Compliance Policy Training, and bioethics standards related to the
conduct of research involving patients and healthy volunteers.
In accordance with Takeda’s global standards, a clinical study will not be initiated or substantially amended until an approval/positive
opinion is obtained from a GCP-compliant Independent Ethics Committee. Takeda has a Global Patient Safety Evaluation organization andResearch and Development Quality and other R&D functions that uphold the protection of patients and ensure quality in our clinical trials
throughout their lifecycle. Internal standards and procedures set expectations for how quality and patient safety is managed across all
countries and regions. We conduct internal audits that assess compliance with our processes and procedures and are subject to regulatory
inspections as well. Escalation processes are in place such that concerns can be raised and are monitored by the Takeda Executive Teamthrough the Global Quality Team. In many jurisdictions, clinical trial participants also have the right to report concerns about theprocessing of their personal information with their local data protection authority. A list of European data protection authorities isavailable here.
The goal of providing patients with early and uninterrupted access to lifesaving treatments is an important component of our Access to
Medicines strategy. Post-Trial Access (PTA) helps to allow continued treatment for eligible clinical trial participants who require access tothe investigational medicine after a clinical trial has completed. More information can be found on Takeda’s PTA mechanisms at
Takeda.com.
Takeda provides clinical trial investigators with site specific patient-level data from investigational sites upon trial completion. Takeda iscommitted to making every effort to submit manuscripts describing the results of Takeda-sponsored phase 2–3 interventional drug
development trials and phase 4 interventional trials using approved compounds, and clinical studies evaluating Takeda’s medical devices,within 18 months after trial completion (for marketed products), after regulatory approval, or after the decision to discontinue or terminate
clinical development of investigational medicines. More information on Takeda’s clinical trials can be found at Takeda Clinical Trials.

SASB INDEX 2

SASB MetricTakeda Disclosure

Safety of Clinical Trial Participants

HC-BP-210a.2

HC-BP-210a.3

Number of FDA Sponsor
Inspections related toclinical trial management
and pharmacovigilancethat resulted in: Voluntary
Action Indicated andOfficial Action IndicatedTotal amount of monetarylosses as a result of legal
proceedings associatedwith clinical trials indeveloping countries

Takeda has demonstrated success in our Good Clinical Practice sponsor inspections for clinical development programs andour Pharmacovigilance (PV) related inspections. The details of the Food and Drug Administration Good Clinical Practice and PV
inspections are in the FDA Inspection Classification Database. All of these inspections had successful outcomes.

FY22 Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries(JPY): 0 ☑
This indicator has been assured by Apex Companies, LLC, an independent professional services company. For details of ourcalculation methodology, other KPIs related to ethics and compliance or for a copy of our Assurance Statement, please see ourSustainability Disclosure under Values-Based Governance Metrics.

Access to Medicines
At Takeda, accelerating patient access to medicines and vaccines is ingrained in our company values. We believe broadening
access to our life-changing medicines and vaccines in underserved communities requires an integrated, sustainable approachthat mobilizes collective efforts. By partnering with diverse stakeholders, we are actively addressing barriers to access andstrengthening healthcare systems to improve lives worldwide.
Our commitment to accelerating patient access to medicines is embedded in our corporate philosophy. It is a commitment wemake worldwide, and across all our therapy areas.

HC-BP-240a.1

Description of actions andinitiatives to promote
access to health careproducts for priority
diseases and in priority
countries as defined by theAccess to Medicine Index

In LMICs and countries with evolving healthcare systems, our Access to Medicines approach focusses on three strategic
imperatives:
1. Collaborate with partners to broaden patient access by strengthening healthcare systems
2. Introduce and support innovative programs that address affordability barriers and enable access to medicines andvaccines. Including:▪ Tiered pricing▪ Takeda’s affordability-based Patient Assistance Programs▪ Value Based Healthcare models
3. Work with policy makers to broaden patient access to our medicines and vaccines
For further information on our position on Access to Medicines please refer to Takeda’s position on Access to Medicines. For
further information on Access to Medicines programs please refer to our biennial Access to Medicines progress report: 2022
Progress Report.

SASB INDEX 3

SASB MetricTakeda Disclosure

Access to Medicines (Continued)
Takeda does not have any products registered on the WHO List of Prequalified Medicinal Products.
At Takeda the vision of our Vaccines Business Unit is to protect the health of people everywhere through vaccines that address
the most important infectious diseases. Our mission is to develop and deliver innovative vaccines that tackle the toughest
problems in public health and improve the lives of people around the world. Takeda’s global vaccine business is applying
innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, COVID-19, pandemic flu and
Zika.

HC-BP-240a.2

List of products on the
WHO List of Prequalified
Medicinal Products as partof its Prequalification of
Medicines Programme(PQP)

For more information on Takeda’s efforts in vaccines please see here.
In addition to our R&D efforts in vaccines, Takeda takes a co-leadership role in the CARE (Corona Accelerated R&D in Europe)
Program and participates in the Global Health Innovative Technology (GHIT) Fund.
The CARE Program is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment
options for COVID-19. The initiative brings together leading expertise across academic, non-profit research institutions andpharmaceutical companies to develop a long-term understanding of the disease and development of therapies for COVID-19
and future coronavirus threats.
The GHIT Fund leverages Japanese expertise and capacity for life-saving health innovations, including drugs, vaccines, anddiagnostics, to combat HIV/AIDS, tuberculosis, malaria, and neglected tropical diseases (NTDs) prevalent in the developingworld. In addition to committing funds to GHIT, Takeda has been working with GHIT Product Development Partners on
research programs for malaria, tuberculosis, and NTDs.
For further information on the CARE Program please see here. For further information on the GHIT Fund please see here.

Affordability and Pricing

HC-BP-240b.1

Number of settlements ofAbbreviated New Drug
Application (ANDA)
litigation that involved
payments and/or
provisions to delay
bringing an authorized
generic product to market
for a defined time period

FY22 Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or
provisions to delay bringing an authorized generic product to market for a defined time period: 0 ☑
Takeda has not entered into any settlement with an ANDA filer that provided any so-called “payment for delay,” including any
agreement by Takeda not to launch an authorized generic version of Takeda’s branded product for a defined time period after
the ANDA-filer’s launch.
This indicator has been assured by Apex Companies, LLC, an independent professional services company. For details of ourcalculation methodology, other KPIs related to ethics and compliance or for a copy of our Assurance Statement, please see ourSustainability Disclosure under Values-Based Governance Metrics.

SASB INDEX 4

SASB MetricTakeda Disclosure

Affordability and Pricing (continued)

HC-BP-240b.2

Percentage change in: (1)average list price and (2)average net price across
U.S. product portfolio
compared to previous year

We disclose our annual average list price and average net price change across our U.S. portfolio on our Pricing Philosophy
Page (under “U.S. Pricing Methodology”). Please see this link for a full explanation of our calculation methodology andhistorical data. In our methodology for calculating the average net price increase, the average net price is weighted by the net
sales and not the list price.
This data is collected on a calendar year, rather than financial year basis, therefore deviates for the period stated for otherinformation in this SASB table.
At present Takeda does not report against this metric. Please see Takeda’s U.S. Pricing Methodology for more information onwhich metrics we communicate related to our U.S. product price changes.

HC-BP-240b.3

Percentage change in: (1)list price and (2) net priceof product with largest
increase compared toprevious year

List of products listed in
the Food and Drug
Administration’s (FDA)
MedWatch Safety Alerts
for Human Medical
Products database
Number of fatalities
associated with products
as reported in the FDA
Adverse Event Reporting
SystemTakeda products with safety alerts can be found in the FDA MedWatch Safety Alerts for Human Medical Products database.

Drug Safety

HC-BP-250a.1

HC-BP-250a.2

Not disclosed

Number of Class I recalls issued in FY22: 0 ☑
Number of Class II recalls issued in FY22: 0 ☑

HC-BP-250a.3

Number of recalls issued,
total units recalled

The scope of this data is U.S. only and includes both enforced and voluntary recalls. Historical product recalls can be found in
the FDA Drug Recalls database.
This indicator has been assured by Apex Companies, LLC, an independent professional services company. For details of ourcalculation methodology, other KPIs related to ethics and compliance or for a copy of our Assurance Statement, please see
our Sustainability Disclosure under Values-Based Governance Metrics.

SASB INDEX 5

SASB MetricTakeda Disclosure

Drug Safety (Continued)

HC-BP-250a.4

HC-BP-250a.5

Total amount of productaccepted for takeback,reuse, or disposal

Number of FDA
enforcement actions
taken in response toviolations of current Good
Manufacturing Practices(cGMP), by typeTakeda supports and participates in pharmaceutical take-back programs in collaboration with relevant industry groups,
including the Pharmaceutical Product Stewardship Working Group (PPSWG). Takeda also supports education of our patientsand end users to encourage safe return or disposal of unwanted or expired medicines and sharps. We will continue to improve
our baseline understanding of unused medicine and sharps takeback efforts including remediation plans and improvement
roadmap as necessary. Through Takeda’s participation in drug take back initiatives we are able to reduce the amount of
medication that can be released into the environment and diminish the potential for abuse of unwanted medication.
Takeda's current support for external drug programs is active in the United States, Brazil and Canada. Through our participationin and collaboration with PPSWG, the initiative has resulted in the collection of approximately 440 tons of unwanted medicine
and approximately 100 tons of sharps-containing drug products for disposal in CY2022. We continue to evaluate programs inother global regions.
Not disclosed

SASB INDEX 6

SASB MetricTakeda Disclosure

Counterfeit Drugs
Takeda is taking a holistic, risk-based approach to identify and lessen the risks of falsified, illegal and other types of suspectproducts to keep our patients safe. A dedicated Global Product Protection team uses a strategic approach by collaboratingwith internal functions and external agencies to carry out this mission.
The following principles guide Takeda's approach to counterfeit, falsified and illegal trading of healthcare products:▪

HC-BP-260a.1

Description of methods
and technologies used tomaintain traceability of
products throughout the
supply chain and prevent
counterfeiting▪
▪
▪

We proactively partner with international and local law enforcement, regulatory agencies, other pharmaceuticalcompanies and industry organizations to combat counterfeiting and illegal trading, while also educating patients, supply
chain partners and customers on the dangers associated with these activities. Through partnerships, such as IFPMA“Fight the Fakes” Campaign and Alliance for Safe On Line Pharmacies (ASOP), we do contribute to grass roots education
to patients
We routinely set high security standards and requirements for supply chain partners worldwide, perform due diligence
and audit against these requirements.
We evaluate, develop and implement innovative anti-counterfeiting solutions for products and packaging to deter anddetect counterfeiting, theft, diversion and tampering.
We detect, investigate and collect evidence against entities suspected of engaging in illegal trade of Takeda product on acontinuous basis, which includes active monitoring and disruption of illegal online pharmacies and other illicit Internet
trading.

For more information please refer to Our Position on Counterfeit, Falsified and Illegal Trading of Health Care Products.

HC-BP-260a.2

HC-BP-260a.3

Discussion of process foralerting customers andbusiness partners ofpotential or known risks
associated withcounterfeit products

We partner actively with international and local law enforcement, regulatory agencies, other pharmaceutical companies andindustry organizations to combat counterfeiting and illegal trading, while also educating patients, supply chain partners andcustomers on the dangers associated with these activities. Through partnerships such as IFPMA “Fight the Fakes” Campaign
and Alliance for Safe Online Pharmacies (ASOP), we contribute to grassroots education for patients.

Number of actions that
led to raids, seizure,arrests, and/or filing of
criminal charges related
to counterfeit productsThis metric is not monitored and disclosed by Takeda. Through active partnerships with law enforcement, regulatory
agencies, other pharmaceutical companies and industry organizations, collective effort is made to combat counterfeit
products

For more information please refer to Our Position on Counterfeit, Falsified and Illegal Trading of Health Care Products.

SASB INDEX 7

SASB MetricTakeda Disclosure

Ethical Marketing

HC-BP-270a.1

HC-BP-270a.2

Total amount ofmonetary losses as aresult of legal
proceedings associatedwith false marketingclaimsDescription of code of
ethics governing
promotion of off-label
use of products

FY22 Total amount of monetary losses as a result of legal proceedings associated with false marketing claims (JPY): 0 ☑
This indicator has been assured by Apex Companies, LLC, an independent professional services company. For details of ourcalculation methodology, other KPIs related to ethics and compliance or for a copy of our Assurance Statement, please see
our Sustainability Disclosure under Values-Based Governance Metrics.
We provide objective and accurate information about our products and the diseases they treat or prevent. We arecommitted to making available information about our products and the diseases they treat or prevent. When we share
information through advertising, promotional or educational activities, we use appropriate channels in accordance withapplicable requirements. Regardless of the channel used, whether digital or in person, we make sure that the information
provided is accurate, fair, balanced and based on scientific evidence. We respect the relationships between patients andhealthcare professionals If patients approach us on matters relating to their medical treatment, we direct them to seek
advice from a healthcare professional. We never promote Takeda products for off-label indications. Inappropriate sales andmarketing practices (including off-label promotion) are listed specifically in our “Global Policy on Issue Reporting and
Handling” as categories of concern that must be raised to Ethics & Compliance upon becoming aware.
Promoting ethics and compliance across Takeda’s operations is the responsibility of our Chief Ethics and Compliance Officer
and our Risk, Ethics and Compliance Committee. They help ensure a coordinated, company-wide approach to ethics andcompliance. Takeda Group companies execute and reinforce their ethics and compliance programs in line with the Takeda
Global Code of Conduct and applicable global policies, as well as local regulations. These policies are approved by theBusiness Sustainability Committee.
Training and education is an important part of our ethics and compliance program. New employees receive ethics andcompliance training, which includes our Global Code of Conduct, Anti-Corruption policy, and other policies and SOPs relevant
to an employee’s position.

SASB INDEX 8

SASB MetricTakeda Disclosure

Employee Recruitment, Development & Retention
Recent world events changed the drug development process and the way we work, requiring us to think differently about how
we attract, hire, develop and retain talent, run clinical trials, and engage with patients. Our efforts described here, along with
our vision and values, are creating the exceptional experience that our employees deserve and that candidates desire. In FY22,
Takeda’s R&D organization attracted and hired a record number of employees, including those in scientists, data engineers
and analysts, clinical research professionals and regulatory affairs roles to deliver for patients. Diverse R&D roles aresupported by enhanced technology, activity-centered workspaces and our R&D hybrid work models that recognize the variety
of work and where that work is best performed. Our data-driven programs and accessible technologies improve collaborationand inclusivity by helping our people stay connected.
Talent Acquisition - Takeda R&D

HC-BP330a.1

Discussion of talent
recruitment and retention
efforts for scientists andresearch and development
personnel

Validating the interest in our people-focused, values-based culture, we saw an increase in external applicants during FY22 froman average of 13 to 31 per month. To achieve diverse candidate slates and interview panels, our focus on inclusion begins
during intake discussions with hiring managers, where we provide DE&I and behavioral-based interview training and acomprehensive toolkit focusing on Takeda Leadership Behaviors. These practices have been adopted where the majority of
R&D roles exist: in the U.S. Europe, Japan and China, where we also now use anti-bias language software to develop inclusive
job descriptions. These efforts helped us continue to grow the R&D organization and hire nearly 1,700 R&D employees in FY22.
We also saw an increase of more than 21% in internal applications and an increase in employee referrals to 27% (from 21% in
FY21).
We now have four external partnerships accelerating our goal to hire undergraduate, U.S.-region interns with underrepresented backgrounds, and our 18-month R&D traineeship program in Switzerland helps to integrate early-career members
to our team by exposing these young professionals to several R&D functions. To quickly create a sense of belonging, empower
and inspire our newer colleagues, we have a comprehensive Global R&D New Hire Onboarding program, targeted functional
onboarding resources, and we encourage hiring managers to pair a ‘Tomodachi’ (Japanese for ‘friend’) with each new
employee, who help with day-to-day questions and cultural acclimation.
Learning & Talent Management – Takeda R&D
The majority of R&D colleagues believe Takeda is a place where everyone can thrive, grow and realize their career potential
according to our employee survey results. We expect that to improve with our recent launch of Bloom, our enterprise-level
learning platform for those who want to expand their knowledge and boost their skill set. At launch, R&D quickly surpassed allother functions with the highest level of Bloom engagement. R&D career-development programs complement the vast
catalogue within Bloom by inspiring change, fostering a culture that increases our talent pipeline, and helping to retain female
leaders. These include:-

The 6-month R&D Mentoring Connection and R&D Women’s Mentoring Network resulting in 12k+ mentoring hours
during FY22

SASB INDEX 9

-

Our 6-month rotational Achieve Program diversifying R&D’s senior leadership pipeline with 23 early-career managers(Achievers) paired during FY22 with sponsors who support their development and promotion toward leadership roles
The GROW Coaching curriculum to further develop critical skills among R&D People Leaders, piloted in FY22 with 21%
participation and continuing in FY23 with both live and self-paced content
26 female participants in FY22 WOMEN Unlimited programs
A series of Knowledge Development Academies focused on the scientific, medical, and technical aspects of clinicaldevelopment
Through our Takeda Physician Scientist Accelerator Program, we hire physicians with patient-care experience and astrong scientific track record transition to a career in pharmaceutical drug development
Science Forum sessions designed to encourage discussion, stimulate ideas, and inspire new approaches to drug
discovery and development

Diversity, Equity & Inclusion – Takeda R&D
As we proceed through the second year of our three-year holistic, data-driven and values-based R&D DE&I Strategy, ourgrowing R&D CAUSE Network of almost 600 colleagues volunteer their time and expertise to help co-create R&D DE&I
solutions. This high level of engagement across all regions ensures a wide variety of input to help maintain Takeda R&D’s
position as an award-winning employer of choice.
Notable solutions to diversify our talent include sourcing early-career talent from underrepresented communities; building
varied candidate slates during succession planning; fostering equitable career opportunities through external partnerships andinternal mentoring programs; and initiating a Diverse Talent Advisory Board to provides varied perspectives as we makedecisions on behalf of the full organization. To develop more inclusive teams, we piloted an interactive program to build
inclusion skills at all role levels, and we expanded our use of a team-effectiveness questionnaire to measure team inclusivity.
Our employees’ interest in creating an inclusive ecosystem is sustained by efforts to improve health equity and supplier
diversity. Our model for inclusive clinical trials requires diversity plans for all U.S. trials and embeds inclusive language
throughout our process; focusing on health equity in communities where we run clinical trials, our Communities As Partners
initiative pairs employee volunteers with opportunities to build trust and long-term investment; and we’re partnering acrossTakeda to boost supplier diversity.
Takeda R&D, we aim to create a culture where people from every background can thrive, grow and realize their career
potential. We strive for an inclusive, equitable and agile culture where action occurs when employees speak up and where we
invest in resources that support each employee’s success. Our priority is to leverage our people-focused programs related towell-being, talent development and DE&I to attract, excite and retain employees, empowering us to deliver for patients.

SASB INDEX 10

SASB MetricTakeda Disclosure

Employee Recruitment, Development & Retention (Continued)

HC-BP-330a.2(1) Voluntary and (2)involuntary turnover rate
for: (a) executives/senior
managers, (b) midlevel
managers, (c)professionals, and (d) allothers

FY22 Total global involuntary turnover rate: 7% ☑
FY22 Total global voluntary turnover rate: 14% ☑
This indicator has been assured by Apex Companies, LLC, an independent professional services company. For details of ourcalculation methodology, other KPIs related to turnover or for a copy of our Assurance Statement, please see ourSustainability Disclosure under People Metrics.

Supply Chain Management

HC-BP-430a.1

Percentage of (1) entity's
facilities and (2) Tier I
suppliers' facilities
participating in the Rx-360
International

Not disclosed

SASB INDEX 11

SASB MetricTakeda Disclosure

Business Ethics

HC-BP-510a.1

Total amount of monetarylosses as a result of legal
proceedings associatedwith corruption andbribery

FY22 Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery: 0 ☑
This indicator has been assured by Apex Companies, LLC, an independent professional services company. For details of ourcalculation methodology, other KPIs related to ethics and compliance or for a copy of our Assurance Statement, please see ourSustainability Disclosures under Values-Based Governance Metrics.
In everything we do we are guided by our values of Takeda-ism, which incorporates Integrity, Fairness, Honesty andPerseverance, with Integrity at the core. Our values are brought to life by taking decisions based on i) the interests ofPatients, ii) Trust with society, iii) Takeda’s reputation and iv) building sustainable business, in that order. We don’t exert
influence over, or provide rewards for, the prescription, use, administration, purchase or recommendation of Takeda
products. We don’t promise, offer or provide any money, gifts, services, hospitality or other items of value as an inducement
for using our products.
To underscore this position, we’ve established various global policies, including the Global Policy on Interactions with HealthCare Professionals and Health Care Entities, the Global Policy on Interactions with Patients and Patient Organizations, theGlobal Policy on Interactions with Government Officials and Government Entities, the Global Anti-Corruption Policy and ourCode of Conduct. Training on all these policies must be completed within 30 days of joining Takeda and refreshers are
required every 2 years for the interactions policies, and annually for our Code of Conduct and Anti-Corruption Policy.

HC-BP-510a.2

Description of code of
ethics governinginteractions with healthcare professionals

Our activities are conducted in compliance with relevant laws of each country, the International Federation of
Pharmaceutical Manufacturers & Associations (IFPMA) Code of Practice and codes of practice established by local industry
associations. We strive to provide medical information in an accurate, fair and balanced way through appropriate channels,
and we review our promotional materials based on internal and external guidelines. These reviews may involve independent
organizations, and regular monitoring also takes place to detect possible misconduct. Separate Standard Operating
Procedures (SOPs) govern reviews and monitoring.
Concerns can also be raised internally through functions such as Human Resources, Legal, Ethics and Compliance, or directly
to senior management. All concerns are addressed promptly, confidentially and respectfully. The Takeda Ethics Line provides
an alternative channel where employees and the general public can raise concerns if they feel Takeda is not living up to ourvalues. It is available online and by phone, 24 hours a day, in 20 languages. If desired, concerns may be raised anonymously.
Timely and appropriate action is taken against any behaviors or practices that are not in line with our values and our Global
Code of Conduct. We are committed to analyzing and understanding the root causes of misconduct to help prevent similar
issues arising again. We continue to strengthen our speak-up culture with general awareness initiatives.
For further information, please see our Code of Conduct or Takeda.com for the mechanisms in place to ensure compliancewith our standards.

SASB INDEX 12

SASB MetricTakeda Disclosure

Activity Metrics
At Takeda our goal is to accelerate patient access to our life-changing medicines worldwide.

HC-BP-000.A

Number of patientstreatedOn an annual basis we report number of patients from underserved communities who have received access to Takeda’s
medicines and vaccines, through our access to medicines innovative affordability programs, health system strengthening
activities, and Takeda-sponsored and -supported clinical trials.
For more information on our KPIs, including historical data and the score of our independent assurance, please see ourSustainability Disclosure under Patient Metrics.

HC-BP-000.B

Number of drugs (1) in
portfolio and (2) inresearch and development(Phases 1-3)

For information on our portfolio and pipeline, see our latest quarterly presentations available here.

SASB INDEX 13

IMPORTANT NOTICE
For the purposes of this notice, “Report” means this document, any oral presentation, any question
and answer session and any written or oral material discussed or distributed by Takeda
Pharmaceutical Company Limited (“Takeda”) regarding this Report. This Report (including any oral
briefing and any question-and-answer in connection with it) is not intended to, and does notconstitute, represent or form part of any offer, invitation or solicitation of any offer to purchase,otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or thesolicitation of any vote or approval in any jurisdiction. No shares or other securities are being offeredto the public by means of this Report. No offering of securities shall be made in the United States
except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption
therefrom. This Report is being given (together with any further information which may be provided
to the recipient) on the condition that it is for use by the recipient for information purposes only
(and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any
failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In thisReport, “Takeda” is sometimes used for convenience where references are made to Takeda and its
subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer tosubsidiaries in general or to those who work for them. These expressions are also used where nouseful purpose is served by identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by
Takeda, or their respective owners.

FORWARD-LOOKING STATEMENTS
This Report and any materials distributed in connection with this Report may contain forwardlooking statements, beliefs or opinions regarding Takeda’s future business, future position andresults of operations, including estimates, forecasts, targets and plans for Takeda. Without
limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”,“hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”,“could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These
forward-looking statements are based on assumptions about many important factors, including thefollowing, which could cause actual results to differ materially from those expressed or implied by
the forward-looking statements: the economic circumstances surrounding Takeda’s global business,
including general economic conditions in Japan and the United States; competitive pressures anddevelopments; changes to applicable laws and regulations, including global health care reforms;
challenges inherent in new product development, including uncertainty of clinical success anddecisions of regulatory authorities and the timing thereof; uncertainty of commercial success for
new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency
exchange rates; claims or concerns regarding the safety or efficacy of marketed products or productcandidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its
customers and suppliers, including foreign governments in countries in which Takeda operates, or onother facets of its business; the timing and impact of post-merger integration efforts with acquiredcompanies; the ability to divest assets that are not core to Takeda’s operations and the timing of any
such divestment(s); the extent to which our internal energy conservation measures and futureadvancements in renewable energy or low carbon energy technology will enable us to reduce ourgreenhouse gas emissions; and other factors identified in Takeda’s most recent Annual Report on
Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission,
available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov.
Takeda does not undertake to update any of the forward-looking statements contained in thisReport or any other forward-looking statements it may make, except as required by law or stock
exchange rule. Past performance is not an indicator of future results and the results or statements of
Takeda in this Report may not be indicative of, and are not an estimate, forecast, guarantee or
projection of Takeda’s future results.

FINANCIAL INFORMATION AND CERTAIN NON-IFRS FINANCIAL
MEASURES
Takeda’s financial statements are prepared in accordance with International Financial ReportingStandards (“IFRS”). This Report and materials distributed in connection with this Report include
certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core
Operating Profit, Core Net Profit, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt,
EBITDA, Adjusted EBITDA and Free Cash Flow. Takeda’s management evaluates results and makes
operating and investment decisions using both IFRS and non-IFRS measures included in this Report.
These non-IFRS measures exclude certain income, cost and cash flow items which are included in, orare calculated differently from, the most closely comparable measures presented in accordance with
IFRS. By including these non-IFRS measures, management intends to provide investors withadditional information to further analyze Takeda’s performance and core results, including whencontrolling for the effect of fluctuations in exchange rates. Takeda’s non-IFRS measures are notprepared in accordance with IFRS and such non-IFRS measures should be considered a supplement
to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes referto as “reported” measures). Investors are encouraged to review the definitions and reconciliations of
non-IFRS financial measures to their most directly comparable IFRS measures, which are in thefinancial appendix appearing at the end of Takeda’s FY2022 investor presentation (available at
takeda.com/investors/financial-results)

EXCHANGE RATESIn this Report, certain amounts presented in Japanese yen have been translated to US dollars solely
for the convenience of the reader. Except where otherwise noted, these convenience translations
have been made at an exchange rate of 1USD = 132.75 JPY, the Noon Buying Rate certified by theFederal Reserve Bank of New York on March 31, 2023. The rate and methodologies used for theseconvenience translations differ from the currency exchange rates and translation methodologies
under IFRS used for the preparation of Takeda’s consolidated financial statements. Thesetranslations should not be construed as a representation that the relevant Japanese yen amounts
could be converted into U.S. dollars at this or any other rate.

MEDICAL INFORMATIONThis Report contains information about products that may not be available in all countries, or may beavailable under different trademarks, for different indications, in different dosages, or in different
strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement
for any prescription drugs including the ones under development.

SASB INDEX 14

SASB INDEX 15